Comprehensive biomarker testing can help your healthcare team identify your appropriate treatment options.

Knowing your non-small cell lung cancer’s biomarkers can help you and your doctor make fully informed decisions about how your cancer will be treated. Ask your healthcare team to perform comprehensive biomarker testing at any decision point before new treatment, including upon diagnosis, recurrence, or progression.

Questions to ask your doctor about comprehensive biomarker testing for lung cancer

1. Ready to get started?
   Ask your doctor these questions and write the answers on the lines below.

   1. Start by asking “Have I received comprehensive biomarker testing?”
      If no, ask “When will my tumor be tested?”

   2. If yes, ask “What do my results mean for my individualized treatment plan?”

      If yes, skip section 2 and move to section 3.

2. Before you get comprehensive biomarker testing, ask these questions:
   “What are you trying to find with biomarker tests?”

   “Have I been tested for these biomarkers?”
   □ EGFR □ ALK □ ROS1 □ NTRK □ HER2 □ KRAS □ BRAF V600E □ MET exon 14 skipping □ RET □ PD-L1
“How are the tests performed?”

“How long will it take to get the test results?”

“Are there any limitations of comprehensive biomarker testing?”

“Will insurance pay for these tests?”

After testing, ask these questions:

“Did you test me for these biomarkers?”

- EGFR
- ALK
- ROS1
- NTRK
- HER2
- KRAS
- BRAF V600E
- MET exon 14 skipping
- RET
- PD-L1

“What are the results of these tests?”

“Can I get a copy of my test results?”

If the test results are negative, ask “Should I be retested?”

If the test results are not clear, ask “Should I be retested? If yes, why and when?”
“If I’ve tested positive for any biomarkers, are there any FDA-approved medicines that target my specific type of non-small cell lung cancer?”

“Are there any clinical trials open to me based on these results?”

Know your biomarkers. Know your options.

To learn more about biomarkers and to read stories by lung cancer patients and survivors who have experienced comprehensive biomarker testing, visit LUNGevity.org/NoOneMissed

Additional notes

---

©2021 LUNGevity